Metvix Daylight PDT in Actinic Keratosis

Galderma R&D406 enrolled

Overview

Prospective non-interventional study conducted in Australia, Brazil, Mexico and Europe to evaluate clinical practice with Metvix Daylight PDT in the treatment of mild to moderate actinic keratosis of the face/scalp and to assess physician and patient satisfaction.

Study Type

OBSERVATIONAL

Enrollment

406

Conditions

Actinic Keratosis

Interventions

MetvixOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients to whom Metvix® Daylight-PDT has already been prescribed by their physician, according to the local label;

Locations (7)

See Jo-Ann

Sydney, New South Wales, Australia

France

Pontoise, France

Italy

L’Aquila, Italy

Alkmaar

Alkmaar, Netherlands

Madrid

Outcomes

Primary Outcomes

Percentage of physician satisfaction assessed on a 4-point scale from very satisfied to not satisfied with the question "Overall are you satisfied with Metvix DL-PDT?"

Time frame: 3 months

Percentage of patient satisfisfaction assessed on a 4-point scale from very satisfied to not satisfied with the question "Overall, how satisfied are you with this treatment?".

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.